BACKGROUND: To compare the clinical performance of a new PCa serum biomarker based on fPSA glycoprofiling to fPSA% and PHI. METHODS: Serum samples from men who underwent prostate biopsy due to increased PSA were used. A comparison between two equal groups (with histologically confirmed PCa or benign, non-cancer condition) was used for the clinical validation of a new glycan-based PCa oncomarker. SPSS and R software packages were used for the multiparametric analyses of the receiver operating curve (ROC) and for genetic algorithm metaheuristics. RESULTS: When comparing the non-cancer and PCa cohorts, the combination of four fPSA glycoforms with two clinical parameters (PGI, prostate glycan index (PGI)) showed an area under receiver operating curve (AUC) value of 0.821 (95% CI 0.754-0.890). AUC values were 0.517 for PSA, 0.683 for fPSA%, and 0.737 for PHI. A glycan analysis was also applied to discriminate low-grade tumors (GS = 6) from significant tumors (GS ≥ 7). CONCLUSIONS: Compared to PSA on its own, or fPSA% and the PHI, PGI showed improved discrimination between presence and absence of PCa and in predicting clinically significant PCa. In addition, the use of PGI would help practitioners avoid 63.5% of unnecessary biopsies, while the use of fPSA% and PHI would help avoid 17.5% and 33.3% of biopsies, respectively, while missing four significant tumors (9.5%).

Department of Clinical Research University of Southern Denmark J B Winsløws Vej 23 5000 Odense C Denmark

Department of Glycobiotechnology Institute of Chemistry Slovak Academy of Sciences Dubravska cesta 9 845 38 Bratislava Slovakia

Department of Immunochemistry Diagnostics University Hospital in Pilsen E Benese 1128 13 301 00 Pilsen Czech Republic

Department of Molecular Oncology Cancer Research Institute Biomedical Research Center of the Slovak Academy of Sciences Dubravska cesta 9 845 04 Bratislava Slovakia

Department of Urology Medical University Innsbruck Anichstrasse 35 A 6020 Innsbruck Austria

Department of Urology Odense University Hospital J B Winsløws Vej 4 5000 Odense C Denmark

Glycanostics Ltd Dubravska cesta 9 845 38 Bratislava Slovakia

Zobrazit více v PubMed

Rawla P. Epidemiology of prostate cancer. World J. Oncol. 2019;10:63. doi: 10.14740/wjon1191. PubMed DOI PMC

Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015;65:87–108. doi: 10.3322/caac.21262. PubMed DOI

Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. PubMed DOI

Tkac J., Bertok T., Hires M., Jane E., Lorencova L., Kasak P. Glycomics of prostate cancer: Updates. Exp. Rev. Proteom. 2019;16:65–76. doi: 10.1080/14789450.2019.1549993. PubMed DOI PMC

Tkac J., Gajdosova V., Hroncekova S., Bertok T., Hires M., Jane E., Lorencova L., Kasak P. Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer. Interface Focus. 2019;9:20180077. doi: 10.1098/rsfs.2018.0077. PubMed DOI PMC

Kohaar I., Petrovics G., Srivastava S. A rich array of prostate cancer molecular biomarkers: Opportunities and challenges. Int. J. Mol. Sci. 2019;20:1813. doi: 10.3390/ijms20081813. PubMed DOI PMC

Steuber T., Tennstedt P., Macagno A., Athanasiou A., Wittig A., Huber R., Golding B., Schiess R., Gillessen S. Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies. BJU Int. 2019;123:826–833. doi: 10.1111/bju.14540. PubMed DOI PMC

Bax C., Taverna G., Eusebio L., Sironi S., Grizzi F., Guazzoni G., Capelli L. Innovative Diagnostic Methods for Early Prostate Cancer Detection through Urine Analysis: A Review. Cancers. 2018;10:123. doi: 10.3390/cancers10040123. PubMed DOI PMC

Cohen J.D., Li L., Wang Y., Thoburn C., Afsari B., Danilova L., Douville C., Javed A.A., Wong F., Mattox A., et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–930. doi: 10.1126/science.aar3247. PubMed DOI PMC

Murphy K., Murphy B.T., Boyce S., Flynn L., Gilgunn S., O’Rourke C.J., Rooney C., Stockmann H., Walsh A.L., Finn S., et al. Integrating biomarkers across omic platforms: An approach to improve stratification of patients with indolent and aggressive prostate cancer. Mol. Oncol. 2018;12:1513–1525. doi: 10.1002/1878-0261.12348. PubMed DOI PMC

Josic D., Martinovic T., Pavelic K. Glycosylation and metastases. Electrophoresis. 2019;40:140–150. doi: 10.1002/elps.201800238. PubMed DOI

Rodrigues J.G., Balmaña M., Macedo J.A., Poças J., Fernandes Â., de-Freitas-Junior J.C.M., Pinho S.S., Gomes J., Magalhães A., Gomes C., et al. Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis. Cell. Immunol. 2018;333:46–57. doi: 10.1016/j.cellimm.2018.03.007. PubMed DOI

Ideo H., Kondo J., Nomura T., Nonomura N., Inoue M., Amano J. Study of glycosylation of prostate-specific antigen secreted by cancer tissue-originated spheroids reveals new candidates for prostate cancer detection. Sci. Rep. 2020;10:2708. doi: 10.1038/s41598-020-59622-y. PubMed DOI PMC

Bertok T., Tkac J. Means and Methods for Glycoprofiling of a Protein. WO2019185515A1. [(accessed on 10 March 2020)];2019 Available online: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019185515.

Tosoian J.J., Alam R., Ball M.W., Carter H.B., Epstein J.I. Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy. Nat. Rev. Urol. 2018;15:55. doi: 10.1038/nrurol.2017.134. PubMed DOI

Loeb S., Catalona W.J. The Prostate Health Index: A new test for the detection of prostate cancer. Ther. Adv. Urol. 2014;6:74–77. doi: 10.1177/1756287213513488. PubMed DOI PMC

Klocker H., Golding B., Weber S., Steiner E., Tennstedt P., Keller T., Schiess R., Gillessen S., Horninger W., Steuber T. Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer. BJUI Compass. 2020;1:15–20. doi: 10.1002/bco2.8. PubMed DOI PMC

Dwek M.V., Jenks A., Leathem A.J.C. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Clin. Chim. Acta. 2010;411:1935–1939. doi: 10.1016/j.cca.2010.08.009. PubMed DOI

Hagiwara K., Tobisawa Y., Kaya T., Kaneko T., Hatakeyama S., Mori K., Hashimoto Y., Koie T., Suda Y., Ohyama C., et al. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer. Int. J. Mol. Sci. 2017;18:261. doi: 10.3390/ijms18020261. PubMed DOI PMC

Yoneyama T., Ohyama C., Hatakeyama S., Narita S., Habuchi T., Koie T., Mori K., Hidari K.I.P.J., Yamaguchi M., Suzuki T., et al. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. Biochem. Biophys. Res. Commun. 2014;448:390–396. doi: 10.1016/j.bbrc.2014.04.107. PubMed DOI

Ishikawa T., Yoneyama T., Tobisawa Y., Hatakeyama S., Kurosawa T., Nakamura K., Narita S., Mitsuzuka K., Duivenvoorden W., Pinthus J.H. An automated micro-total immunoassay system for measuring cancer-associated α2, 3-linked sialyl N-glycan-carrying prostate-specific antigen may improve the accuracy of prostate cancer diagnosis. Int. J. Mol. Sci. 2017;18:470. doi: 10.3390/ijms18020470. PubMed DOI PMC

Zijlstra C., Stoorvogel W. Prostasomes as a source of diagnostic biomarkers for prostate cancer. J. Clin. Investig. 2016;126:1144–1151. doi: 10.1172/JCI81128. PubMed DOI PMC

Aigner F., Schäfer G., Steiner E., Jaschke W., Horninger W., Herrmann T.R.W., Nagele U., Halpern E.J., Frauscher F. Value of enhanced transrectal ultrasound targeted biopsy for prostate cancer diagnosis: A retrospective data analysis. World J. Urol. 2012;30:341–346. doi: 10.1007/s00345-011-0809-6. PubMed DOI

Mitterberger M., Horninger W., Aigner F., Pinggera G.M., Rehder P., Steiner E., Wiunig C., Reissigl A., Frauscher F. Contrast-enhanced colour Doppler-targeted vs a 10-core systematic repeat biopsy strategy in patients with previous high-grade prostatic intraepithelial neoplasia. BJU Int. 2010;105:1660–1662. doi: 10.1111/j.1464-410X.2009.08963.x. PubMed DOI

Llop E., Ferrer-Batalle M., Barrabes S., Enrique Guerrero P., Ramirez M., Saldova R., Rudd P.M., Aleixandre R.N., Comet J., de Llorens R., et al. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes. Theranostics. 2016;6:1190–1204. doi: 10.7150/thno.15226. PubMed DOI PMC

Endt K., Goepfert J., Omlin A., Athanasiou A., Tennstedt P., Guenther A., Rainisio M., Engeler D.S., Steuber T., Gillessen S., et al. Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PLoS ONE. 2017;12:e0181557. doi: 10.1371/journal.pone.0181557. PubMed DOI PMC

Team R.C. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna. [(accessed on 3 June 2017)]; Available online: www.R-project.org.

Carpenter J., Bithell J. Bootstrap confidence intervals: When, which, what? A practical guide for medical statisticians. Stat. Med. 2000;19:1141–1164. doi: 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F. PubMed DOI

Bertok T., Lorencova L., Hroncekova S., Gajdosova V., Jane E., Hires M., Kasak P., Kaman O., Sokol R., Bella V., et al. Advanced impedimetric biosensor configuration and assay protocol for glycoprofiling of a prostate oncomarker using Au nanoshells with a magnetic core. Biosens. Bioelectron. 2019;131:24–29. doi: 10.1016/j.bios.2019.01.052. PubMed DOI PMC

Bertok T., Lorencova L., Hroncekova S., Gajdosova V., Jane E., Hires M., Kasak P., Kaman O., Sokol R., Bella V., et al. Synthesis and characterization of Au nanoshells with a magnetic core and betaine derivatives. MethodsX. 2019;6:1999–2012. doi: 10.1016/j.mex.2019.08.017. PubMed DOI PMC

Pihikova D., Pakanová Z., Nemcovic M., Barath P., Belicky S., Bertok T., Kasak P., Mucha J., Tkáč J. Front cover: Sweet characterisation of prostate specific antigen using electrochemical lectin-based immunosensor assay and MALDI TOF/TOF analysis: Focus on sialic acid. Proteomics. 2016;16:3085–3095. doi: 10.1002/pmic.201500463. PubMed DOI PMC

Chocholova E., Bertok T., Jane E., Lorencova L., Holazová A., Belicka L., Belicky S., Mislovičová D., Vikartovská A., Imrich R., et al. Glycomics meets artificial intelligence—Potential of glycan analysis for identification of seropositive and seronegative rheumatoid arthritis patients revealed. Clin. Chim. Acta. 2018;481:49–55. doi: 10.1016/j.cca.2018.02.031. PubMed DOI

Chocholova E., Bertok T., Lorencova L., Holazova A., Farkas P., Vikartovska A., Bella V., Velicova D., Kasak P., Eckstein A.A., et al. Advanced antifouling zwitterionic layer based impedimetric HER2 biosensing in human serum: Glycoprofiling as a novel approach for breast cancer diagnostics. Sens. Actuators B Chem. 2018;272:626–633. doi: 10.1016/j.snb.2018.07.029. DOI

Scrucca L. GA: A Package for Genetic Algorithms inR. J. Stat. Softw. 2013;53:1–37. doi: 10.18637/jss.v053.i04. DOI

James G., Witten D., Hastie T., Tibshirani R. An Introduction to Statistical Learning: With Applications in R. Springer Science and Business Media LLC; New York, NY, USA: 2013.

Johnson P., Vandewater L., Wilson W., Maruff P., Savage G., Graham P., Macaulay L.S., Ellis K.A., Szoeke C., Martins R.N., et al. Genetic algorithm with logistic regression for prediction of progression to Alzheimer’s disease. BMC Bioinform. 2014;15:S11. doi: 10.1186/1471-2105-15-S16-S11. PubMed DOI PMC

Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study